NCT01813734View on ClinicalTrials.gov

Ponatinib in Advanced NSCLC w/ RET Translocations

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

August 31, 2018

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Ponatinib

28 day cycle

Trial Locations (5)

43210

Ohio State University, Columbus

92868

University of California, Irvine, Orange

Unknown

University of Maryland, Baltimore

Karmanos Cancer Institute, Detroit

02115

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01813734 - Ponatinib in Advanced NSCLC w/ RET Translocations | Biotech Hunter | Biotech Hunter